Rosuvastatin Cipla 5/10/20/40 mg FC tablets
PDF Leaflet Revision Date: 02 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
To reduce cardiovascular risk and treat hypercholesterolaemia.
Dosage (summary)
5 to 40 mg orally once daily; starting dose 5 mg.
Onset of Action / Duration
Onset: 1 week, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
- Asian ancestry
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Ciclosporin
- Gemfibrozil
- Fibrates
- Protease inhibitors
- Warfarin
Contraindications
- Hypersensitivity to rosuvastatin
- Active liver disease
- Severe renal impairment
- Concomitant ciclosporin
- Pregnancy and lactation
- Myopathy
Common side effects
- Myalgia
- Headache
- Constipation
- Nausea
- Dizziness
Counselling Points
- Report muscle pain or weakness immediately.
- Avoid alcohol consumption.
- Use effective contraception during treatment.
Serious warnings
- Risk of myopathy and rhabdomyolysis
- Monitor renal function at high doses
- Increased liver transaminases
Important Disclaimer
The Rosuvastatin Cipla 5/10/20/40 mg FC tablets professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
